Abstract:A 43-year-old female nonsmoker patient presented to our hospital in September 2014 with a 2-month history of coughing and a 1-month history of back pain. A bronchoscopic biopsy showed that the patient had a stage IV (T2N2M1) lung adenocarcinoma (Fig. 1) and magnetic resonance imaging revealed lumbar and brain metastases. The patient was treated with 2 cycles of chemotherapy (pemetrexed and cisplatin), followed by bone radiotherapy (T8-T10, DT3000 cGy) and whole-brain radiotherapy (DT3000 cGy). The efficacy was stable disease. The amplification refractory mutation system method showed that the adenocarcinoma cells harbored an exon 19 deletion of the EGFR gene. We analyzed the initial tissue upon which was only found EGFR p.E746_S752delinsV by next-generation sequencing (3D Medicines, Shanghai, China). Thus, the patient was administrated erlotinib (150 mg daily) from November 2014 to August 2017. Thus far, no progression of the original lung mass has been identified; however, multiple bone, liver, and adrenal metastases were noted, and the brain metastases had enlarged according to the Response Evaluation Criteria in Solid Tumors version 1.1 in August 2017. Hence, we concluded that the patient had EGFR–tyrosine kinase inhibitor (TKI) resistance. Therefore, a repeat liquid biopsy was performed, which showed an acquired MET-UBE2H fusion gene by next-generation sequencing (3D Medicines) (Fig. 2). The disease progressed, so the patient was switched to crizotinib (250 mg twice daily) in September 2017 (Fig. 3A). She achieved a partial response and progression-free survival at more than 6.5 months (Fig. 3B).Figure 2MET-UBE2H fusion is clinically actionable. (A) the Integrative Genomics Viewer snapshot of MET-UBE2H. (B) Schematic representation of the MET-UBE2H fusion protein domain structure.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3Computed tomography (CT) scans show: (A) before crizotinib therapy, and (B) CT of the chest showed partial response after months of crizotinib treatment.View Large Image Figure ViewerDownload Hi-res image Download (PPT) We presented the first case involving a patient with the MET-UBE2H fusion gene who experienced a dramatic and durable antitumor response to crizotinib after acquired resistance to EGFR-TKI. We assume that MET-UBE2H is a novel resistance gene rearrangement to EGFR-TKI which has not been described. Nowadays, there are two chief mechanisms of resistance that have been reported: approximately 50% of patients develop secondary EGFR mutations; and 15% to 20% of patients experience MNNG HOS Transforming gene (MET) amplification.1Kobayashi S. Boggon T.J. Dayaram T. et al.EGFR mutation and resistance of non–small-cell lung cancer to gefitinib.N Engl J Med. 2005; 24: 786-792Crossref Scopus (3476) Google Scholar MET directly activates downstream signaling pathways of EGFR through upregulation and activation of P13K/AKT signaling, leading to tumor resistance to EGFR-TKI.2Engelman J.A. Zejnullahu K. Mitsudomi T. et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.Science. 2007; 18: 1039-1043Crossref Scopus (3900) Google Scholar The patient described herein showed a significant response to crizotinib. Crizotinib inhibits MET kinase and blocks the MET signaling pathway, therefore limiting the expression of the MET fusion gene.3Reck M. Popat S. Reinmuth N. et al.Metastatic non–small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2014; 25: 27-39Crossref Scopus (588) Google Scholar, 4Gridelli C. Rossi A. Airoma G. et al.Treatment of pulmonary neuroendocrine tumours: state of the art and future developments.Cancer Treat Rev. 2012; 25: 466-472Google Scholar Recent research has focused on MET exon 14 alterations, but the treatment of more complex structural rearrangements has not been established. In addition, KIF5B and STARD3NL have been observed as a fusion partner for MET. It has been reported that KIF5B-MET and STARD3NL-MET gene fusion benefits from treatment with crizotinib.5Plenker D. Bertrand M. de Langen A.J. et al.Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients.Clin Cancer Res. 2018; 15: 1337-1343Crossref Scopus (49) Google Scholar We recommend that more effort be exerted to explore the mechanism underlying resistance to EGFR-TKI and treatment of complex structural MET gene rearrangements. Crizotinib may be used to overcome EGFR-TKI resistance conferred by MET gene rearrangements. In such a situation, a second biopsy should be routinely performed after acquisition of resistance to the EGFR-TKI to examine the MET gene rearrangements, as well as other mechanisms of resistance, if possible. This study was supported in part by grants from the Science and Technology Planning Project of Zhejiang Province (2015C33194) and the National Clinical Key Specialty Construction Program (2013).

Acquired Met Y1248h and D1246n Mutations Mediate Resistance to Met Inhibitors in Non-Small Cell Lung Cancer

Mutations in the MET Tyrosine Kinase Domain and Resistance to Tyrosine Kinase Inhibitors in Non-Small-cell Lung Cancer

Supplemental Figure 2 Clonal Progression of P02 and P04. from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Novel Resistance Mechanisms to First Generation EGFR Tyrosine Kinase Inhibitors: A Perspective Study in NSCLC Patients Using Targeted Next Generation Sequencing.

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer after Development of EGFR-TKI Resistance

The Coexistence of MET Over-Expression and an EGFR T790M Mutation is Related to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

Supplemental Figure 4 Dose-dependent Inhibition from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing

Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors

Integrative Genomic Analysis of Drug Resistance in MET Exon 14 Skipping Lung Cancer Using Patient-Derived Xenograft Models

MET-UBE2H Fusion As a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (Tkis).

Clinical Analysis by Next-Generation Sequencing for NSCLC Patients with MET Amplification Resistant to Osimertinib

Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy

Supplemental Figure 3 Functional Validations of MET Y1248H and D1246N from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Abstract 1945: Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor osimertinib and KRAS-G12C inhibitor sotorasib in lung cancer

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling